A Phase 2 interventional study of Astaxanthin and Protandim in Amyotrophic Lateral Sclerosis ALS, sponsored by Duke University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Duke University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 118th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2024, is one of 89 in phase 2, and was the 361st registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 8 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy \& axonal transport, and mitochondrial dysfunction. Once a disease category is established, participants in this study will receive one of four individualized supplements for 6 months and we will determine whether these are slowing ALS progression: Astaxanthin will be given for the category of neuroinflammation, Protandim for oxidative stress, Melatonin for impaired autophagy and MitoQ for mitochondrial dysfunction. During the first 3 months, participants will have routine monitoring and in months 3 through 9 they will receive the assigned supplement.
This will be a widely inclusive, largely remote/virtual, two-center, open-label pilot trial utilizing 50 participants as their own controls. Following informed consent and screening, participants will provide demographics, disease characteristics, co-morbidities, and concomitant medications. They will have a baseline ALSFRS-R score obtained and blood will be drawn for DIGAP classification, PBMCs (which will be used to generate iPSCs from which motor neurons and/or microglia can be generated), baseline mechanistic biomarkers and baseline neurofilament light chain. A urine pregnancy test will be obtained for pre-menopausal females who have not had one by their own doctor in the past 7 days. Each month after that, they will be contacted by phone by study coordinators to review adverse events, new co-morbidities, and concomitant medications, and to generate a new ALSFRS-R score. At month 3, DIGAP classification will be revealed to each participant and based on this, they will receive 1 of 4 treatments. They will take their assigned treatment for 6 months. At months 3, 5 and 9 they will be asked to return for in person blood draws for repeat mechanistic biomarkers and neurofilament light chain measurements. All of the described blood tests and investigational treatments are being performed exclusively for research purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants in this category are expected to have inflammation in their brains and spinal cords.
Drug: Astaxanthin
Study participants in this category are expected to have too many damaging "free radical" chemicals in their brains and spinal cords.
Drug: Protandim
Study participants in this category are expected to have motor neurons that have trouble transporting materials up and down their length, and/or trouble with the turnover of damaged proteins and intracellular structures.
Drug: Melatonin
Study participants in this category are expected to have motor neurons that are unable to produce normal amounts of energy.
Drug: MitoQ
Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).
Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.
ALS Functional Rating Scale, Revised (ALSFRS-R)
A quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine patients' assessments of their capability and independence in 12 functional activities. The total score ranges from 0 (maximum disability) to 48 (normal function). A higher score indicates greater function.
Time frame: Baseline, month 3, month 5, and month 9
Neurofilament Light Chain Levels
Neurofilament light chain levels are elevated in the spinal fluid and the blood of patients with ALS and other neurodegenerative diseases, and higher levels predict more severe disease progression. These levels rise dramatically when asymptomatic carriers of ALS-causing genetic mutations begin to convert to an ALS phenotype.
Time frame: Baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment)
Neuroinflammation Measured by C-reactive Protein (CRP)
Used to measure neuroinflammation. CRPs are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.
Time frame: Baseline, 3 months, 5 months and 9 months
Neuroinflammation Measured by Monocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2
Used to measure neuroinflammation. CCL2s are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.
Time frame: Baseline, 3 months, 5 months and 9 months
Oxidative Stress Measured by Total Antioxidant Capacity (TAC)
Used to measure oxidative stress.
Time frame: Baseline, 3 months, 5 months, and 9 months
Oxidative Stress Measured by Uric Acid Levels.
Uric acid is an antioxidant and levels of uric acid have been reported to be lower in ALS subjects and correlated with progression. It has also been shown to be responsive to treatments in trials
Time frame: Baseline, 3 months, 5 months, and 9 months
Mitochondrial Dysfunction Measured by Lactate
Compromised mitochondrial oxidative phosphorylation shifts the cellular bioenergetic system to anaerobic respiration and increases the level of lactate. Lactate has been used as a biomarker for mitochondrial disease in many previous studies.
Time frame: Baseline, 3 months, 5 months, and 9 months
Impaired Autophagy Measured by Beclin-1
To measure impaired autophagy, we will use Beclin-1. This highly conserved eukaryotic protein has a major regulatory role in autophagy. It is a component of the phosphatidylinositol-3-kinase (PI3K) complex which mediates vesicle-trafficking thereby inducing autophagy. Beclin-1 dysfunction has been implicated in many disorders, including cancer and neurodegenerative diseases.
Time frame: Baseline, 3 months, 5 months, and 9 months
Neuroinflammation Measured by Chitotriosidase (CHIT1)
Used to measure neuroinflammation. CHIT1 is known to be abnormal in patients with ALS, its levels correlate with disease progression and they can be altered by drugs in trials.
Time frame: Baseline, 3 months, 5 months and 9 months
Participants were recruited from the Duke and Temple ALS Clinic populations in 2024.
| Milestone | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Started | 3 | 15 | 14 | 18 |
| Completed | 1 | 15 | 13 | 14 |
| Not completed | 2 | 0 | 1 | 4 |
| Withdrew: Death | 0 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 |
A quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine patients' assessments of their capability and independence in 12 functional activities. The total score ranges from 0 (maximum disability) to 48 (normal function). A higher score indicates greater function.
| score on a scale | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 34.3 ± 6.1 | 32.1 ± 9.7 | 36.8 ± 6.4 | 36.1 ± 6.7 |
| 3 months | 32.5 ± 7.8 | 31.1 ± 9.5 | 34.4 ± 5.3 | 34.1 ± 10.2 |
| 5 months | 28.5 ± 0.7 | 29.1 ± 9.2 | 34.2 ± 5.2 | 33.1 ± 9.7 |
| 9 months | 26.0 ± NA | 28.0 ± 9.0 | 30.8 ± 6.4 | 33.0 ± 6.5 |
Neurofilament light chain levels are elevated in the spinal fluid and the blood of patients with ALS and other neurodegenerative diseases, and higher levels predict more severe disease progression. These levels rise dramatically when asymptomatic carriers of ALS-causing genetic mutations begin to convert to an ALS phenotype.
| log (pg/mL) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 4.4 ± 1.0 | 4.6 ± 0.8 | 4.5 ± 0.9 | 4.6 ± 1.0 |
| 3 months | 4.5 ± 0.6 | 4.7 ± 0.8 | 4.6 ± 0.8 | 4.5 ± 1.0 |
| 5 months | 4.6 ± 0.7 | 4.6 ± 0.8 | 4.5 ± 0.9 | 4.5 ± 1.0 |
| 9 months | 5.5 ± NA | 4.6 ± 0.8 | 4.5 ± 0.9 | 4.3 ± 1.1 |
Used to measure neuroinflammation. CRPs are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.
| ng/dL | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 1469.8 ± 815.0 | 2152.9 ± 1531.9 | 1126.8 ± 1094.4 | 1502.8 ± 1195.0 |
| 3 months | 5113.4 ± NA | 1662.0 ± 1377.6 | 878.2 ± 852.5 | 1882.0 ± 1402.3 |
| 5 months | 2120.3 ± 2422.9 | 2621.2 ± 1931.9 | 2308.4 ± 2373.9 | 1440.8 ± 1582.5 |
| 9 months | 1685.9 ± NA | 7900.4 ± 8769.4 | 2388.5 ± 2525.5 | 6351.9 ± 11469.2 |
Used to measure neuroinflammation. CCL2s are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.
| pg/mL | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 443.3 ± 34.0 | 397.6 ± 150.2 | 336.3 ± 112.4 | 366.9 ± 118.1 |
| 3 months | 373.5 ± 31.8 | 368.2 ± 112.0 | 297.6 ± 97.9 | 399.1 ± 145.1 |
| 5 months | 275.0 ± 50.9 | 328.8 ± 153.2 | 291.6 ± 103.8 | 353.1 ± 195.0 |
| 9 months | 184.0 ± NA | 224.7 ± 63.3 | 187.2 ± 33.4 | 239.0 ± 92.9 |
Used to measure oxidative stress.
| mmol/L | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 196.3 ± 23.8 | 190.5 ± 46.2 | 203.2 ± 66.0 | 192.5 ± 35.4 |
| 3 months | 181.2 ± 83.1 | 148.9 ± 90.9 | 172.2 ± 60.2 | 157.3 ± 88.8 |
| 5 months | 259.0 ± 2.8 | 294.0 ± 71.9 | 263.3 ± 61.6 | 304.8 ± 113.0 |
| 9 months | 296.9 ± NA | 294.7 ± 71.9 | 273.2 ± 103.9 | 299.6 ± 44.5 |
Uric acid is an antioxidant and levels of uric acid have been reported to be lower in ALS subjects and correlated with progression. It has also been shown to be responsive to treatments in trials
| mg/dL | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 10.0 ± 3.0 | 9.9 ± 2.0 | 8.7 ± 3.3 | 8.8 ± 1.8 |
| 3 months | 10.2 ± 2.7 | 9.5 ± 2.4 | 10.2 ± 2.8 | 10.4 ± 2.6 |
| 5 months | 11.1 ± 3.1 | 11.1 ± 3.1 | 10.4 ± 2.2 | 11.3 ± 2.9 |
| 9 months | 7.5 ± NA | 8.7 ± 1.1 | 7.0 ± 1.5 | 7.2 ± 1.6 |
Compromised mitochondrial oxidative phosphorylation shifts the cellular bioenergetic system to anaerobic respiration and increases the level of lactate. Lactate has been used as a biomarker for mitochondrial disease in many previous studies.
| mmol/L | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Baseline | 5.8 ± 1.0 | 6.3 ± 1.2 | 6.7 ± 1.3 | 6.3 ± 1.4 |
| 3 months | 8.0 ± 1.3 | 7.2 ± 1.2 | 7.3 ± 1.3 | 7.6 ± 1.1 |
| 5 months | 9.6 ± 1.2 | 16.7 ± 5.4 | 14.6 ± 5.9 | 15.2 ± 6.3 |
| 9 months | 6.4 ± NA | 7.2 ± 2.4 | 7.8 ± 1.7 | 7.2 ± 1.4 |
To measure impaired autophagy, we will use Beclin-1. This highly conserved eukaryotic protein has a major regulatory role in autophagy. It is a component of the phosphatidylinositol-3-kinase (PI3K) complex which mediates vesicle-trafficking thereby inducing autophagy. Beclin-1 dysfunction has been implicated in many disorders, including cancer and neurodegenerative diseases.
Results for this outcome have not been posted.
Used to measure neuroinflammation. CHIT1 is known to be abnormal in patients with ALS, its levels correlate with disease progression and they can be altered by drugs in trials.
Results for this outcome have not been posted.
Collected over Up to approximately 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neuroinflammation | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Oxidative Stress | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Impaired Autophagy and Axonal Transport | 1/14 (7.1%) | 1/14 (7.1%) | 14/14 (100%) |
| Mitochondrial Dysfunction | 2/18 (11.1%) | 2/18 (11.1%) | 18/18 (100%) |
| Event | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| Lung InfectionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/15 | 0/14 | 2/18 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/3 | 0/15 | 0/14 | 2/18 |
| Heart AttackCardiac disorders | 0/3 | 0/15 | 1/14 | 0/18 |
| MeningitisInfections and infestations | 0/3 | 0/15 | 1/14 | 0/18 |
| FallInjury, poisoning and procedural complications | 0/3 | 0/15 | 1/14 | 0/18 |
| Cardiac DisorderCardiac disorders | 0/3 | 0/15 | 1/14 | 0/18 |
| Kidney StonesRenal and urinary disorders | 0/3 | 0/15 | 1/14 | 0/18 |
| Thromboembolic EventCardiac disorders | 0/3 | 0/15 | 0/14 | 1/18 |
| SepsisInfections and infestations | 0/3 | 0/15 | 0/14 | 1/18 |
| DiverticulitisGastrointestinal disorders | 0/3 | 0/15 | 0/14 | 1/18 |
| Event | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/3 | 15/15 | 14/14 | 12/18 |
| Upper respiratory infectionInfections and infestations | 0/3 | 2/15 | 5/14 | 2/18 |
| InsomniaGeneral disorders | 1/3 | 0/15 | 0/14 | 0/18 |
| Gastrointestinal DisorderGastrointestinal disorders | 0/3 | 1/15 | 0/14 | 5/18 |
| Pain in extremityGeneral disorders | 0/3 | 0/15 | 3/14 | 0/18 |
| Nasal congestionGeneral disorders | 0/3 | 0/15 | 2/14 | 0/18 |
| NauseaGastrointestinal disorders | 0/3 | 0/15 | 2/14 | 0/18 |
| Urinary respiratory tract infectionInfections and infestations | 0/3 | 2/15 | 0/14 | 0/18 |
| Sore throatGeneral disorders | 0/3 | 0/15 | 0/14 | 2/18 |
| Allergic rhinitisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/15 | 1/14 | 0/18 |
| Age, Continuous(years) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction | Total |
|---|---|---|---|---|---|
| Mean | 65.6 ± 5.7 | 58.2 ± 10.0 | 49.6 ± 10.6 | 59.3 ± 16.5 | 56.7 ± 13.3 |
| Sex: Female, Male(Participants) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 5 | 6 | 16 |
| Male | 1 | 12 | 9 | 12 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 3 | 14 | 13 | 18 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 13 | 14 | 18 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Neuroinflammation | Oxidative Stress | Impaired Autophagy and Axonal Transport | Mitochondrial Dysfunction | Total |
|---|---|---|---|---|---|
| United States | 3 | 15 | 14 | 18 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in May 2025, 11 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's 11 months is below that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Astaxanthine · Protandim · Melatonin · Mitoquinone
Amyotrophic Lateral Sclerosis →